• Sustainable ICV infusion of MG (6 days) in rats induces a cognitive deficit.
H I G H L I G H T S
• Sustainable ICV infusion of MG (6 days) in rats induces a cognitive deficit.
• A single high-dose MG infusion (1 day) reduces anxiety-like behavior in rats.
• MG causes persistent alterations in the hippocampus, but not in the frontal cortex.
• MG infusion modifies GLO1 activity, AGEs content and glutamate uptake.
a b s t r a c t a r t i c l e i n f o

Introduction
It is well recognized that diabetes can affect cognition [9, 50] . Studies with diabetic patients indicate that they present a cognitive decline that particularly affects learning and memory, behavioral flexibility and mental speed [12, 19, 65, 68, 69] . Consistent data suggest that diabetes is related to a high risk of developing Alzheimer's disease (AD) [9, 36, 47] . In this context, some molecules have been studied and suggested as mediators of the association between diabetes and brain damage, such as elevated levels of glucose and accumulation of advanced glycation end products (AGEs) [10, 37, 80] .
Several findings support the hypothesis that protein glycation is involved in the pathophysiology of diabetes and AD. Glycation is defined as spontaneous, non-enzymatic reaction of protein with saccharides and saccharide derivatives [61] . Studies have found elevated concentrations of AGEs and one of its main precursors, methylglyoxal (MG), in the plasma of diabetes patients and in the cerebrospinal fluid (CSF) of patients with AD [1, 5, 6, 40] . Moreover, it has been proposed that the polymerization of β-amyloid and tau hyperphosphorylation are processes exacerbated by glycation [43, 44] . Clinical reports indicate that AGEs Physiology & Behavior 164 (2016) [93] [94] [95] [96] [97] [98] [99] [100] [101] are co-located with senile plaques and neurofibrillary tangles [38, 67] and that the senile plaques of AD patients contain about three times more AGEs than observed in age-matched controls [77] . In addition, elevated levels of MG have been described in experimental studies using the streptozotocin-induced diabetes model [13] , in association with cognitive impairments in memory and learning [33] . Studies investigating the chronic oral or intraperitoneal administration of MG have found induced endothelial insulin resistance and suggested the use of this protocol as an animal model of diabetes [41, 54] . Furthermore, clinical findings indicate that higher serum levels of MG are associated with a faster rate of cognitive decline in elderly individuals [4] .
Studies that have looked at the glyoxalase pathway, which is a major defense against MG toxicity [73] , have strengthened the idea that an appropriate regulation of MG levels is important to avoid cognitive impairment [29, 71] . It has been shown that increases in glyoxalase 1 (GLO1) expression and activity significantly decrease MG and AGEs levels in plasma [13] and diminish AGEs levels in the hippocampus, as well as reversing the cognitive decline in an animal model of diabetes [45] . Moreover, other behavioral alterations have been related to MG levels, but these findings are still in discussion [30, 71] . Reports have demonstrated that MG administration reduces anxiety-like behavior and that GLO1 increases anxiety by reducing levels of MG [23, 30, 32] . Recent findings have also identified the role of MG levels in epilepsy and suggested that the inhibition of GLO1 attenuates seizures [21] . Nevertheless, it has been proposed, through clinical studies, that aberrant expression of GLO1 is linked to major depression, panic disorders and schizophrenia [29] and that higher doses of MG can cause locomotor depression, ataxia and hypothermia in mice [21] .
We hypothesized that elevated MG concentrations, induced by intracerebroventricular (ICV) MG infusion, lead to cognitive decline and changes in anxiety-related behavior in Wistar rats. This study investigated behavioral and biochemical alterations induced by different procedures of ICV MG administration.
Material and methods
Materials
Methylglyoxal (MG) solution (40% in H 2 O), 2′,7′-dichlorofluorescein diacetate (DCF-DA), standard glutathione (GSH), Triton X-100, ophthaldialdehyde, S100B protein, anti-S100B (SH-B1), L-glutamate, ophenylenediamine (OPD), meta-phosphoric acid, γ-glutamylhydroxamate acid and N-methyl-D-glucamine were purchased from Sigma (Saint Louis, MO, USA). L- [2, H] glutamate was purchased from Amersham International (United Kingdom). Polyclonal anti-S100B and polyclonal anti-GFAP were purchased from DAKO (São Paulo, SP, Brazil), anti-rabbit peroxidase linked antibody was purchased from GE Healthcare (Little Chalfont, United Kingdom). Anti-AGE antibody (6D12) was purchased from Cosmo Bio (Tokyo, Japan). All other chemicals were purchased from local commercial suppliers.
Animals
Fifty-eight male Wistar rats (90-days old) were obtained from our breeding colony (Department of Biochemistry, UFRGS, Porto Alegre, Brazil). The animals were maintained under controlled light and environmental conditions (12 h light/12 h dark cycle at a constant temperature of 22 ± 1°C) and had free access to commercial chow and water. All animal experiments were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. , revised 1996, and following the regulations of the local animal house authorities.
Rats were divided into 4 groups: SHAM (N = 16), MG 1 day (N = 10), MG 3 days (N = 16) and MG 6 days (N = 16). After behavioral tasks, rats were anesthetized, as subsequently described, for CSF puncture and posterior hippocampal and frontal cortex slice preparation, aiming to evaluate reactive species levels, glutathione (GSH) contents, GLO1 and glutamine synthetase (GS) activities, glutamate uptake, S100B secretion, AGEs, S100B and glial fibrillary acidic protein (GFAP) content.
Surgical procedure and treatments
Animals were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) intraperitoneally. The head of the animal was fixed in a stereotaxic instrument, and the skin covering the skull was cut with a 3-cm-long rostro-caudal incision along the midline. After exposure of the skull bone surface, a 27-gauge 9-mm guide cannula was unilaterally placed at 0.9 mm posterior to the bregma, 1.5 mm right from the midline and 1.0 mm above the right lateral brain ventricle. The cannula was implanted 3.0 mm ventral to the superior surface of the skull through a 2-mm hole made in the cranial bone. The positioning of the cannula was fixed with dental acrylic cement, and a screw used for the fixation of the dental acrylic helmet to the bone was used as ground [74] . The appropriate stereotactic location of the cannula had been previously verified by Ponceau-stain injection. After the surgical procedure, rats were placed on a heating pad to maintain body temperature at 37°C and were kept there until recovery from anesthesia. 2) was injected once a day into the capillary tubules, using a Hamilton syringe. MG solution was filter-sterilized (0.22-μm filter) and diluted in vehicle (HBSS).
All animals treated with ICV MG received the same infused final concentration (3 μmol/μL), but the distribution of this total concentration was different among these 3 groups: MG 1 day-one injection; MG 3 days-three injections on alternate days (1 μmol/μL per day); MG 6 days-six injections on 6 subsequent days (0.5 μmol/μL per day). The SHAM group received six injections of vehicle on 6 subsequent days. According to these groups, the single or last ICV MG injection was performed on the same day (see Fig. 1 ). MG was ICV infused based on a Fig. 1 . Schematic representation of the experimental protocol. Surgery corresponds to cannula implantation; ICV infusion of MG or vehicle was performed after 5 days of recovery (MG 1 day = one injection at 11th day (3 μmol/μL); MG 3 days = three injections on alternate days-7th, 9th and 11th (1 μmol/μL per day); MG 6 days and SHAM = six injections on the subsequent 6 days-6th-11th (MG = 0.5 μmol/μL per day)); behavioral tests were performed following this sequence: OF (2 days), OR and Y-maze (24 h of interval between each task); cerebrospinal fluid, hippocampi and frontal cortex were harvested for biochemical analysis.
previous study [30] . The animals were submitted to behavioral tasks at 3 weeks after MG injection. The tasks were performed following the following sequence: open field (OF) test, object-recognition (OR) task and Y-maze, always with a 24-h interval between each behavioral test. Twelve days after the Y-maze test the rats were submitted to biochemical analysis (approximately 6 weeks after MG injection) (see Fig. 1 ).
Behavioral tests
All behavioral experiments were conducted in a sound-attenuated room under low-intensity light (12 lx) and were monitored by an experimenter who was unaware of the drug treatments. All apparatuses were cleaned with a 10% ethanol solution and then dried with a paper towel after each trial.
Locomotion, anxiety-related behavior and habituation
The motor activity, the anxiety-related behavior and the habituation of rats were evaluated in the OF test. The OF was made of wood covered with impermeable wood, had a black floor measuring 60 cm 2 , and was surrounded by 60-cm-high walls. This test consists of a large arena containing an aversive central area and represents a widely used paradigm for the evaluation of both locomotor activity and anxiety-like behavior [59] . In the habituation task, the rats were allowed to explore the OF for 10 min on two consecutive days. The distance traveled was registered on the first day as an index of general activity [58, 63] . Number of entries and distance traveled in peripheral area (adjacent to the walls-peripheral locomotion), number of entries and distance traveled in central area (away from the walls-central locomotion) and percentage of central locomotion in relation to the total locomotion (peripheral locomotion plus central locomotion) and the time spent in center of the OF were registered on the first day. These measurements were used as an index of anxiety-like behavior. The rats were individually placed in the center of the OF, and behavioral parameters were recorded and subsequently elaborated with an automated activity-monitoring system (Any-maze; Stoelting, Wood Dale, IL, USA).
Object-recognition
The OR task was conducted in the OF, as previously described ( [26] adapted by [55] ). It consisted of three distinct phases: habituation, sample, and discrimination. In the habituation phase, the rats were allowed to explore the OF for 10 min on two consecutive days. In the sample phase, two identical objects (C1 and C2; cubes) were placed in opposite corners of the OF, 20 cm distant from the walls and~60 cm apart from each other, and the rats were allowed to explore them for 5 min. After the end of the sample phase, the rats were removed from the OF and kept in the home cage. After a delay period of 30 min, in the discrimination phase, an identical copy of the familiar object (C3) and a novel Tshaped object (T) were placed in the locations previously occupied by C1 and C2, and the rats were allowed to explore the objects for 5 min. All of the objects were constructed with plastic LEGO blocks. The locations of the objects were counterbalanced in each session. The time spent by the rats exploring each object was monitored with a video system placed in an adjacent room. Exploration of an object was defined as sniffing or touching the object with the nose and/or forepaws. To analyze the cognitive performance of rats, a recognition index was calculated in each session, as follows; time exploring the familiar or novel Tshaped object × 100/time exploring both objects [11, 46] .
Y-maze
The spatial recognition memory of animals was investigated using a Y-maze paradigm. The apparatus consisted of three arms (50 × 10 × 20 cm 3 and 120°apart) made of black plastic, placed in a room with visual cues on the walls. Y-maze testing consisted of two trials separated by an interval of 1 h [20, 56] . In the first trial, the animal was placed at the end of one arm and allowed access to that arm and another arm for 5 min. The third arm (the novel arm) was blocked by a guillotine door. The rat was then removed from the maze and returned to its home cage. For the second trial, the rat was placed back into the start arm of the maze and given free access to all three arms for 5 min. The number of entries and the time spent in each arm were recorded. The percentage of entries and time spent in the novel arm was compared to random exploration of the three arms of the maze (i.e., 33%).
2.5. Biochemical analysis 2.5.1. Obtaining CSF and hippocampal and frontal cortex samples Animals were anesthetized and then positioned in a stereotaxic holder and CSF was obtained by cisterna magna puncture using an insulin syringe (27 gauge × 1/2″ length). CSF samples were frozen (−20°C) until further analysis [28, 64] . The animals were killed by decapitation, the brains were removed and placed in cold sodium phosphate buffer with the following composition (in mM): 51.33 NaCl, 19.13 NaH 2 PO 4 ·H 2 O, 81.01 Na 2 HPO 4 , pH 7.4. The hippocampi and frontal cortex were dissected and transverse slices of 0.3 mm were obtained using a McIlwain Tissue Chopper [53] . Slices were then frozen (− 80°C) or transferred immediately to 24-well culture plates for measuring glutamate uptake, as subsequently described.
Evaluation of intracellular reactive species production
Intracellular reactive species production was detected via the nonfluorescent cell-permeating compound, 2′,7′-dichlorofluorescein diacetate (DCF-DA). DCF-DA is hydrolyzed by intracellular esterases and then oxidized by reactive species to a fluorescent compound, 2′,7′-dichlorofluorescein (DCFH). Slices were treated with DCF-DA (10 μM) for 30 min at 37°C. Following DCF-DA exposure, the slices were lysed into PBS with 0.2% Triton X-100. Fluorescence was measured on a plate reader (Spectra Max Gemini XPS, Molecular Devices, USA) with excitation at 485 nm and emission at 520 nm. All procedures were performed in the dark, and blanks containing only DCF-DA were processed for measurement of autofluorescence [60] . Values were obtained as fluorescence units/mg protein and were expressed as percentages of the control.
GSH content assay
Intracellular GSH levels were measured as previously described [14] . This assay detects only the reduced glutathione content. Slices were homogenized in sodium phosphate buffer (0.1 M, pH 8.0) containing 5 mM EDTA and protein was precipitated with 1.7% meta-phosphoric acid. Supernatant was assayed with o-phthaldialdehyde (1 mg/mL methanol) at room temperature for 15 min. Fluorescence was measured using excitation and emission wavelengths of 350 and 420 nm, respectively. A calibration curve was employed using standard GSH solutions (0-500 μM). GSH concentrations were calculated as nmol/mg protein and were expressed as percentages of the control.
GLO1 activity assay
Slices were lysed and homogenized in sodium phosphate buffer, pH 7.4. Subsequently, slices were centrifuged at 13,000 rpm for 15 min at 4°C and the supernatant was used for enzymatic activity and protein content measurements. GLO1 activity was assayed according to [49] with some modifications. The assay was carried out in 96-well microplates using a microplate spectrophotometer (UV Star-Greiner). The reaction mixture (200 μL/well) contained 50 mM sodium-phosphate buffer pH 7.2, 2 mM methylglyoxal (MG) and 1 mM GSH (pre-incubated for 30 min at room temp). Protein from the sample (10-20 μg per well) was added to the buffer. The formation of S-(D)-lactoylglutathione was linear and monitored at 240 nm for 15 min at 30°C. A unit of GLO1 activity is defined as the amount of enzyme that catalyzes the formation of 1 μmol of S-(D)-lactoylglutathione per minute. Specific activity was calculated in milliunits per milligram of protein (mU/mg protein) and was expressed as percentages of the control.
AGEs content
AGEs were measured by an enzyme-linked immunosorbent assay, as previously described [34] , with some modifications. The wells of a microtiter plate were coated overnight with 0.1 μg protein in 0.1 mL of 50 mM carbonate bicarbonate buffer (pH 9.6). The wells were washed three times with washing buffer (PBS containing 0.05% Tween 20) and then incubated for 3 h with 2% albumin from chicken egg white to block nonspecific binding. Subsequently, wells were washed again with washing buffer and incubated with 100 μL anti-AGE (6D12) for 1 h. After three washes, wells were incubated with 100 μL peroxidaseconjugated secondary antibody for 60 min. The reactivity of peroxidase was determined by incubation with o-phenylenediamine dihydrochloride (OPD) for 30 min. The reaction was stopped by the addition of 50 μL sulfuric acid (3 M). Absorbance measurements were taken at 492 nm. Results were calculated and expressed as percentages of the control.
GFAP content
Enzyme-linked immunosorbent assay for GFAP was carried out, as previously described [75] , by coating the microtiter plate with 100 μL samples for 24 h at 4°C. Incubation with a rabbit polyclonal anti-GFAP for 1 h was followed by incubation with a secondary antibody conjugated with peroxidase for 1 h, at room temperature. A colorimetric reaction with o-phenylenediamine was measured at 492 nm. The standard human GFAP (from Calbiochem) curve ranged from 0.1 to 5.0 ng/mL. Data were calculated as ng/μg total protein and were expressed as percentages of the control.
2.5.7. S100B measurement S100B was measured by an enzyme-linked immunosorbent assay, as previously described [42] . Briefly, 50 μL of sample (previously diluted when necessary) plus 50 μL of Tris buffer were incubated for 2 h on a microtiter plate previously coated overnight with monoclonal anti-S100B (SH-B1) antibody. For measurement of S100B content in the hippocampus and frontal cortex slices, polyclonal anti-S100 and peroxidase-conjugated anti-rabbit antibodies were incubated at the same time for 60 min at 37°C. The microtiter plate was rinsed three times with a wash solution between each step of the technique. A colorimetric reaction with o-phenylenediamine was measured at 492 nm. The standard S100B curve ranged from 0.010 to 10 ng/mL. For CSF samples, polyclonal anti-S100 antibody was incubated for 30 min, and then peroxidase-conjugated anti-rabbit antibody was added for an additional 30 min, at 37°C. The standard S100B curve ranged from 0.002 to 1 ng/ mL. Data were calculated as ng/μg protein and were expressed as percentages of the control.
Glutamate uptake assay
Glutamate uptake was performed as previously described [70] . Slices were incubated at 37°C in HBSS, as described previously. The assay was started by the addition of 0.1 mM L-glutamate and 0.66 μCi/ mL L- [2, H] glutamate. Incubation was stopped after 5 min by removing the medium and rinsing the slices twice with ice-cold HBSS. The slices were then lysed in a 0.5 M NaOH solution. Sodium-independent uptake was determined using N-methyl-D-glucamine instead of NaCl. Sodium-dependent glutamate uptake was obtained by subtracting the non-specific uptake from the total uptake to obtain the specific uptake. Radioactivity was measured in a scintillation counter. Results were calculated as nmol/mg protein/min and were expressed as percentages of the control.
GS activity
The enzymatic activity of glutamine synthetase was determined using the procedures described previously [51] with modifications. Briefly, slices were homogenized in 50 mM imidazole. Homogenates were incubated with (mM): 50 imidazole, 50 hydroxylamine, 100 L-glutamine, 25 sodium arsenate dibasic heptahydrate, 0.2 ADP, 2 manganese chloride, pH 6.2 for 15 min at 37°C. The reactions were terminated by the addition of 0.2 mL of 0.37 M FeCl 3 , 200 mM trichloroacetic acid, and 670 mM HCl. After centrifugation, the absorbance of the supernatant was measured at 530 nm and compared to the absorbance generated by standard quantities of γ-glutamylhydroxamate acid treated with ferric chloride reagent. Glutamine synthetase activity was expressed as μmol/mg protein/h and was expressed as a percentage of the control. Fig. 2 . Effect of ICV administration of MG on habituation (A), locomotor activity (B) and anxiety-related behavior (C, D) in the OF task. The rats were exposed for 10 min to the OF on day 1, and 24 h later they were exposed again to the OF on day 2 and the behavioral parameters were evaluated 3 weeks after the single or last ICV MG injection. Data are expressed as mean ± S.E.M. (N = 9-16 animals per group). Data were analyzed by two-way ANOVA with regard to days of OF and treatments (A). Statistical significance is indicated in the graph in bold type. Bonferroni's post hoc test was performed and statistical significance is indicated in the graph with letters. Groups without a common letter statistically differ, assuming p b 0.05. Other data were analyzed by one-way ANOVA followed by Duncan's test (B, C, D) . Bars without a common letter statistically differ, assuming p b 0.05.
Protein determination
Protein content was measured by Lowry's method using bovine serum albumin as standard [57] .
Statistical analysis
Data are reported as means ± standard errors and analyzed statistically by one-way or two-way analysis of variance (ANOVA), followed by Duncan's or Bonferroni's test, when the F-test was significant. The OR task was analyzed by a one-sample t-test to determine whether the recognition index was different from a chance performance (50%). Differences were considered to be significant when p b 0.05. All analyses were performed using the SPSS software package 20.0 or Prism 5.0 (GraphPad).
Results
Behavioral effects
We first tested the effect of the ICV administration of MG on the performance of adult Wistar rats in the OF test. Locomotion activity (Fig.  2B ) and anxiety-like behavior (Fig. 2C, D) were evaluated 3 weeks after the single or last ICV MG injection. Habituation in the OF task, measured as the distance traveled, was measured on day 1 and 2 ( Fig. 2A) . Locomotor activity was not altered by MG injection as compared to the SHAM group (Fig. 2B ) (F (3,47) = 6.5, p = 0.0009); however, anxiety-like behavior was significantly reduced when MG was administrated in single dose (MG 1 day), as demonstrated by the increase in the central locomotion (Fig. 2C) , measured as a ratio of distance traveled (F (3,45) = 18.3, p b 0.0001), the percentage of visits (F (3,44) = 6.8, p = 0.0007; data not shown) and the time spent in the center of the OF (Fig. 2D) (F (3,46) = 4.1, p = 0.0120). To evaluate the habituation of rats, two-way ANOVA revealed that the factor "Days in the OF" and the factor "Treatments" were statistically significant, where no interaction between these factors was observed. Taken together, results indicate that the habituation of all groups occurred in the OF task on two consecutive days (24 h of interval). Bonferroni's post hoc analysis showed that MG, only when administered on alternative days (MG 3 days), significantly affected behavior in the OF when compared to the SHAM group on day 2 ( Fig. 2A) .
Subsequently, we assessed the effect of MG administration on the sample and discrimination phase in the OR task. In the sample phase (Fig. 3A) , the groups evaluated did not differ significantly in comparison with chance performance, indicating similar exploration of both familiar objects. In the discrimination phase (Fig. 3B) , the SHAM group increased the recognition index (t (5) = 3.1, p = 0.0254) and, interestingly, MG administration for 6 consecutive days decreased the recognition index in comparison with chance performance (t (12) = 5.4, p = 0.0002), suggesting memory impairment in MG 6 days using the OR task.
To further investigate the effects of MG injection on short-term spatial memory the rats were subjected to a Y-maze test one day after the OR task. There were no significant differences between the groups tested, as evaluated by the ratio of time (F (3,49) = 2.2, p = 0.0969) and the ratio of visits in the novel arm (F (3, 50) = 0.3, p = 0.8109) (Fig. 4A, B) , suggesting no loss of spatial recognition memory. However, it should be noted that MG 1 day significantly increased the time spent in the novel arm, when measured in seconds (F (3, 49) = 3.9, p = 0.0128; data not shown), and the percentage of the time spent in the novel arm in relation to the total time spent in apparatus (sum of time in two familiar arms, novel arm and central area) (F (3, 49) = 3.9, p = 0.0139; data not shown), when compared to all the other groups. Data indicate that MG when administrated in a single dose (MG 1 day) could interfere in short-term spatial memory, as detectable using these specific parameters in the Y-maze test.
Biochemical findings
In order to determine whether long-term biochemical alterations occur following ICV administration of MG, we evaluated reactive species formation, GSH content, GLO1 activity and AGEs content in the hippocampus and frontal cortex of these animals, to determine whether oxidative stress and dicarbonyl-related alterations are induced by this treatment. Interestingly, reactive species formation (data not shown) (F (3, 52) = 0.7, p = 0.5295 hippocampus; F (3,52) = 0.6, p = 0.5767 cortex) and GSH content (Fig. 5A, B) (F (3,49) = 3.0, p = 0.0358 hippocampus; F (3, 46) = 0.3, p = 0.8113 cortex) were not altered in either of the structures studied, when comparing the treated groups with the SHAM group. On the other hand, a significant increase in GLO1 activity was observed following ICV administration of MG for 1 day (Fig. 5C , D) (F (3,50) = 3.8, p = 0.0142 hippocampus; F (3,49) = 0.6, p = 0.5803 cortex) and a significant increase in AGEs content was verify following administration of MG for 6 days (Fig. 5E, F) (F (3,48) = 3.4, p = 0.0245 hippocampus; F (3, 45) = 0.9, p = 0.4303 cortex); these alterations were observed solely in the hippocampus.
We next investigated whether the astroglial-related parameters, namely GFAP and S100B content, could be altered by ICV administration of MG, since S100B has been proposed to be a marker of astroglial activation in brain disorders [66] and GFAP elevation is a strong sign of astrogliosis, which can occur in several conditions involving brain injury [24] . No significant differences was observed in the GFAP (F (3,35) = 1.1, p = 0.3603 hippocampus; F (3, 48) = 0.7, p = 0.5198 cortex) and S100B content (F (3, 53) = 0.8, p = 0.4549 hippocampus; F (3,53) = 1.4, p = 0.2518 cortex) in the hippocampus (Fig. 6A, B) and frontal cortex (data not shown) following the infusion of MG. Interestingly, a significant increase in CSF S100B was determined following the administration of MG for 1 day and for 3 days, as compared to the SHAM group (data not shown) (F (3,35) = 7.6, p = 0.0005).
Finally, we investigated some hippocampal glutamatergic metabolic parameters and found that the glutamate uptake was significantly reduced when MG was administrated in a single dose (MG 1 day) (Fig.  7A) (F (3,51) = 3.3, p = 0.0274). GS activity was not altered by MG infusion in this brain region (Fig. 7B) (F (3,46) = 0.5, p = 0.6274).
Discussion
In this study, we evaluated behavioral and biochemical parameters to explore the hypothesis that increased exogenous levels of MG, induced by ICV infusion, could lead cognitive impairment in rats. Our hypothesis was based on findings from clinical and experimental studies demonstrating that diabetes leads to cognitive impairment [9, 36] and dicarbonyl stress, and that increased AGEs levels may mediate this decline [37] . Recently, a large body of evidence has indicated that MG and AGEs interfere in cognition processes [4, 15, 33, 45, 78] . In fact, high consumption of dietary AGEs induces increased levels of circulating AGEs, which are associated with cognitive decline in mice and humans [15, 78] . It has been suggested that serum levels of MG may contribute to declines in attention and cognition and may interfere in processing speed [4, 33, 78] . Furthermore, immunohistochemical study from AD brains has demonstrated a reduction on GLO1 staining concomitantly with augmentation of AGEs deposits, particularly during the late stage of AD [39] , indicating the involvement of glycation in cognitive decline.
It is important to mention that we used a battery of behavioral tests to screen for possible MG-induced changes in learning and memory behavior; batteries of tests have been suggested to be better than using just one test by some authors [18, 35] and ensure superior interpretation of results. Furthermore, the sequence of the behavioral tasks was established to impose an increasingly averse environment on the animal, according to the proposal of the test performed. In the OR test, we found that a sustained administration of MG (MG 6 days) decreased the recognition index, indicating an impairment in discriminatory memory in this specific group. However, a single injection of MG (MG 1 day) generated apparent improvements in short-term spatial memory, as demonstrated by some parameters of the Y-maze test (data not shown). Moreover, the data obtained for habituation in the OF test, Ymaze and OR tasks, which involve spatial and discriminatory memory, respectively, indicate that MG infusion did not impair learning-memory . GFAP and S100B content in the hippocampus of rats submitted to ICV MG injection. Hippocampi were dissected out and the contents of GFAP (A) and S100B (B) were measured approximately 6 weeks after the single or last ICV MG injection. Data are expressed as mean ± S.E.M (N = 8-11 animals per group for GFAP and N = 10-16 animals per group for S100B), assuming SHAM value as 100%. SHAM values of GFAP and S100B content are 12.8 and 1.6 ng/μg protein in hippocampus, respectively. Data were analyzed by one-way ANOVA, assuming p b 0.05.
processes, when evaluated at 3 weeks after infusion using these tasks. Therefore, it is not possible to establish whether MG elevation can alter cognitive function in the same way using our protocol of ICV MG infusion, together with the distinct tasks performed. Elevated levels of MG are known to induce locomotor depression and ataxia [23] and these alterations could compromise behavioral evaluation. However, our MG administration study protocol did not cause alterations in locomotor activity, as shown by the behavioral tasks performed and demonstrated by the total distance traveled in the OF (day 1).
The results of the OF test demonstrated that high levels of MG (MG 1 day) were able to generate anxiolytic-related behavior in rats. Based on these results, it may be suggested that exogenously elevated levels of MG in the brain may cause persistent changes in anxiety-like behavior. This idea is also supported by a mouse model in which a persistent (5 weeks) decrease in anxiety-like behavior was observed following chronic endogenous elevation of MG, induced by local inhibition of GLO1 expression with RNA interference [32] . MG has also been reported to have a rapid anxiolytic effect (16 h after the last injection) in mouse [30] . These data suggest that the permanent augmentation of MG (probably more than 6 days of infusion) may be necessary to induce longterm anxiolytic-like behavior in rats.
We found apparent opposing effects of MG on cognition and anxiety. It may be suggested that the hippocampus is functionally different, with ventral subregions that are more involved in anxiety-related processes and dorsal subregions that are more involved in cognitive processes [3] . In addition, it is proposed that hippocampal functions (such as memory and anxiety) are mediated by different neurotransmitter systems (such as GABAergic and glutamatergic) and/or different receptor subtypes within the hippocampus [25] . Therefore, in our study, the reduction in anxiolytic-like behavior (observed with 3 μmol/μL MG, single dose) and impairment in discriminatory recognition (observed with 0.5 μmol/μL/day for 6 days), could be due to the distinct tissue distribution of MG after different protocol of ICV administration. In other words, these two procedures of administration could trigger different MG molecular targets and sites of metabolism.
The role of GLO1 in mental disease is in constant discussion, with a particular focus on dicarbonyl substrate concentration, mainly MG [29] . The local overexpression of the GLO1 gene in the mouse brain results in increased anxiety-like behavior by reducing MG levels [32] . Our findings regarding the effects of ICV MG infusion support data in the literature that suggest a link between GLO1 and anxiety, making GLO1 a possible target for anxiolytic-drug development [22, 71] via alterations in MG levels in the brain. Aberrant expression of GLO1 has been shown to be involved in other psychiatric disorders, such as major depression, panic disorders and schizophrenia [29] . These reports indicate that the presence of adequate concentrations of MG in the brain may play an important physiological role in the prevention of brain disorders [29] .
We were, thus, interested in determining which late biochemical alterations may be induced by MG in the hippocampus and cortex areas, which are brain regions that are sensitive to damage in AD [27] . To explore this, we performed biochemical analyses at about 6 weeks after MG ICV injection. MG administration in the ventricle system did not alter the oxidative parameters, as verified by DFCH oxidation and GSH content measurement. However, in vitro and in vivo studies have reported that MG mediates toxicity in tissues via oxidative stress [13, 31, 45] . The absence of evidence of oxidative stress in our study does not rule out the possibility that these biochemical changes occurred acutely prior to measuring these biochemical parameters.
The increased activity of GLO1 in the hippocampus may prevent accumulation of MG-derived AGEs, as observed following the elevation of MG by a single administration (MG 1 day). In the early and middle AD stages, an upregulation of GLO1 protein has been reported, and the authors suggest that this augmentation could compensate and maintain physiological MG levels [40] . However, this increase in protein levels did not reflect the alterations from activity of GLO1. In fact, GLO1 activity did not change in different stages of AD [39] . Consequently, the increase in AGEs has been shown to be prevented by the overexpression of GLO1 [72] . On the other hand, following 6 days of successive MG administration (MG 6 days), there was a significant increase in AGEs content in the hippocampus, while the activity of GLO1 was preserved, indicating that the GLO1 failed to abolish the augmentation of MG that was induced by lower and consecutive doses of MG.
AGEs have been proposed to contribute to the pathogenesis of AD by cross-linking with cytoskeletal proteins and rendering them insoluble, consequently compromising transport processes and contributing to neuronal dysfunction and death. In addition, extracellular accumulation of AGEs chronically activated micro-and astroglial cells, which constantly produced free radicals and neurotoxic cytokines [37] . In AD and other aging-related neurodegenerative diseases, impaired astrocyte functions, as well as recruitment and activation of glial cells occur even before the appearance of pathological and clinical signs of disease [27, 52] . Glial activation in response to injury stimuli commonly involve changes in GFAP and the S100B protein [8, 28, 64] . No changes in GFAP nor S100B content were observed in the present study, indicating that ICV MG administration did not induce gliosis. However, gliosis induced by MG and/or AGEs, has been demonstrated by augmentations in GFAP in different studies [15, 16] and, interestingly, overexpression of GLO1 attenuates this astrocyte activation [7] . In dementia models, CSF S100B was found to be diminished after weeks of brain hypoperfusion or of streptozotocin or okadaic acid administration [8, 17, 76] . In contrast, in injuries caused by acute ICV LPS infusion, S100B in the CSF increased [28] . We found a significant increment in CSF S100B following the administration of MG for 1 and 3 days.
We clearly observed hippocampus susceptibility following ICV MG administration, when compared to frontal cortex. As such, we investigated the effects of MG elevation on some glutamatergic functions in hippocampus. Astrocytes regulate synaptic levels of glutamate from glutamate uptake activity [27] , avoiding glutamatergic excitotoxicity, which has been related to damage in AD and other brain disorders [2, 48] . Interestingly, a single MG administration (MG 1 day) induced a significant reduction in glutamate uptake. This finding could suggest that astrocyte transporter activity is impaired, possibly due to the direct and irreversible binding of MG, leading to glutamate excitotoxicity. We also evaluated an important enzyme involved in the regulation of glutamine levels in astrocytes, GS. However, no changes in GS activity were observed with the ICV MG infusion.
Our study presents some limitations; firstly, the protocol using ICV administration (instead of GLO1 inhibition) imposed limitations regarding the time of increased levels of MG. Whereas GLO1 embryonic deletion is lethal to rodents and humans [62] , the modeling of GLO1 by local inhibition of protein expression could be complementary to studying the chronic effects of MG. Secondly, the age of the animals, since older animals may be more susceptive to elevation of MG and cognitive decline. Thirdly, the meaning of the results obtained by behavioral tests could be benefited by complementary tasks, as a water maze, which would strengthen the data and could clarify the susceptibility of hippocampus from MG action. Finally, the times for behavioral and neurochemical analysis are different, hampering possible correlations. Further in vivo studies will be required to determine, conclusively, the involvement of dicarbonyl-induced glycation and related alterations in the etiology of human neurodegenerative disease [79] .
We investigated the effects of ICV infused MG, employing three procedures: a) a single administration (MG 1 day), or b) a sustainable administration for 6 subsequent days (MG 6 days), or c) an intermediary infusion on alternate days (MG 3 days). Notice that our data were obtained with in vivo MG administration and they are not easily comparable with in vitro data [16, 31] where MG concentrations are potentially toxic to in vivo condition. When taken together, our results indicate no impairment in memory processes following a single administration of MG. However, based on previous reports suggesting that elevated MG may be indicative of brain cell injury initiated before clinically-evident cognitive compromise [4] . As such, we hypothesize that chronically elevated MG concentrations that persist in the brain tissue could compromise memory functions. Accordingly, our data indicate an impairment in discriminatory memory following MG administration for 6 days. Together with the biochemical findings showing that the AGEs content increased at 6 weeks after MG administration and the observed susceptibility of the hippocampus to this MG exposure, we suggest that cognitive decline occurs as a result of glycation-linked alterations over time.
Conclusions
Our findings support that MG infusion can mediate behavioral and biochemical alterations in rat brain after long-term exposure by changed learning-memory processes and biochemical functions of hippocampus; also by the reduction the anxiety-like behavior. Therefore, we suggest that the time and the levels of exogenous MG determine the different features that can be seen in diabetic patients.
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